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Abstract
Aims—Sputum poses a critical diffusional barrier that strongly limits the efficacy of drug and
gene carriers in the airways of individuals with cystic fibrosis (CF). Previous attempts to enhance
particle penetration of CF sputum have focused on either reducing its barrier properties via
mucolytics, or decreasing particle adhesion to sputum constituents by coating the particle surface
with non-mucoadhesive polymers, including polyethylene glycol (PEG). Neither approach has
enabled particles to penetrate expectorated sputum at rates previously observed for non-
mucoadhesive nanoparticles in human cervicovaginal mucus. Here, we sought to investigate
whether a common mucolytic, N-acetyl cysteine (NAC), in combination with dense PEG coatings
on particles, can synergistically enhance particle penetration across fresh undiluted CF sputum.
Materials & methods—We used high-resolution multiple particle tracking to measure the
diffusion of uncoated and PEG-coated nanoparticles in native and NAC-treated CF sputum.
Results—We discovered that 200 nm particles, if densely coated with PEG, were able to
penetrate CF sputum pretreated with NAC with average speeds approaching their theoretical
speeds in water. Based on the rapid penetration of PEG-coated particles in NAC-treated sputum,
we determined that the average spacing between sputum mesh elements was increased from 145 ±
50 nm to 230 ± 50 nm upon NAC treatment. Mathematical models based on particle transport
rates suggest as much as 75 and 30% of 200 and 500 nm PEG-coated particles, respectively, may
penetrate a physiologically thick NAC-treated CF sputum layer within 20 min. Uncoated particles
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were trapped in CF sputum pretreated with NAC nearly to the same extent as in native sputum,
suggesting that NAC treatment alone offered little improvement to particle penetration.
Conclusion—NAC facilitated rapid diffusion of PEG-coated, muco-inert nanoparticles in CF
sputum. Our results provide a promising strategy to improve drug and gene carrier penetration in
CF sputum, offering hope for improved therapies for CF.
Keywords
cystic fibrosis sputum; mesh spacing; multiple particle tracking; N-acetyl cysteine; polyethylene
glycol
Mutations of the gene encoding the cystic fibrosis transmembrane conductance regulator
(CFTR) protein lead to improper regulation of ions and water content of mucus in the
airways of cystic fibrosis (CF) patients [1,2]. This results in the formation of markedly more
viscoelastic and purulent sputum that is, at best, less efficiently cleared by ciliary action [1].
Reduced sputum clearance can lead to increasing obstruction of the airways and a massive
inflammatory response triggered by bacterial infection [3]. The barrier property of CF
sputum is evident by poor gene transfer with lipid- and adenovirus-based gene carriers in
sputum-covered versus sputum-depleted tissues [4], which may partially account for the
failures in CF gene therapy trials to date. The sputum barrier has also likely thwarted the
development of localized, long-lasting antibiotic and anti-inflammatory medications, since
aerosol particles capable of sustained drug release are typically trapped in the luminal CF
sputum and, thus, readily removed by mucociliary and cough clearance. Diffusion chamber,
fluorescence recovery after photobleaching and multiple particle tracking studies all
demonstrate that the transport of conventional polymeric nanoparticles, 30–500 nm in
diameter, is strongly retarded in CF sputum [5–7]. Numerous reviews on the potential of
aerosol-based CF therapies cite the thick mucus layer as a challenge [8,9] and ‘one of the
greatest obstacles to overcome’ [10]. Thus, the development of drug and gene carriers
capable of efficiently penetrating the CF sputum barrier is sorely needed for improved CF
therapies [11].
We have recently engineered polymeric nanoparticles as large as 200 nm, which can
penetrate CF sputum with approximately 100-fold higher geometric mean effective
diffusivity (<Deff>) than similarly sized conventional polystyrene (PS) particles [12,13].
This was accomplished by decreasing the adhesive interactions between particles and
sputum constituents by densely coating particles with low-molecular-weight polyethylene
glycol (PEG) [13–15]. Nevertheless, the <Deff> of 200 and 500 nm coated particles were
approximately 15- and 400-fold lower in CF sputum than their rates in cervicovaginal mucus
(CVM), respectively [14], most likely due to increased adhesivity and elevated steric
obstruction from the sticky and dense CF sputum mesh [11,16,17].
To further enhance particle penetration across CF sputum, we sought to reduce the
diffusional barrier properties of CF sputum by adjuvant mucolytics treatment. Mucolytic
agents are currently used to reduce the bulk viscoelasticity of CF sputum by cleaving
sputum constituents and, therefore, improve sputum clearance and lung function [18].
Commonly used mucolytic agents include recombinant human DNase (rhDNase, also
known as dornase alpha or Pulmozyme®) and N-acetyl cysteine (NAC; Mucomyst®).
RhDNase, which cleaves linear DNA in CF sputum, has been studied as an adjuvant for
particle transport in CF sputum, but offered little to no improvement [6,7,19]. NAC, a
mucolytic that cleaves disulfide bonds of mucin fibers, has been shown to reduce the
viscosity of mucus/sputum in vitro [20] and in vivo [21]. Inhalation of a lysine salt of NAC,
nacystelyn, has also been shown to be well tolerated by CF patients and to lead to a dose-
dependent decrease in sputum viscoelasticity and solid content [22]. Nevertheless, NAC has
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never been tested as an adjuvant to enhance particle transport in purulent CF sputum. We
thus sought to test whether NAC, in combination with dense PEG coatings on particles, can
further enhance particle penetration across fresh undiluted CF sputum.
Materials & methods
CF sputum collection
Sputum spontaneously expectorated by male and female CF patients, aged 24–55 years, was
collected at the Johns Hopkins Adult Cystic Fibrosis Center, MD, USA. The procedures
conformed to the ethical standards of the Johns Hopkins Medicine Institutional Review
Board. Two to four samples were acquired from the weekly CF outpatient clinic, placed on
ice upon collection and during transport, pooled together to minimize patient-to-patient
variation, and studied the same day. The total number of individual samples used for the
present study was 12.
Nanoparticle preparation & characterization
Fluorescent carboxyl-modified PS nanoparticles (PS-COOH), sized 200 and 500 nm
(Molecular Probes, OR, USA), were covalently modified with 3.4 kDa diamine PEG (NH2-
PEG-NH2; Nektar Therapeutics, CA, USA) at a 3:1 PEG:COOH ratio, as described
previously [14]. Fluorescent carboxylate-modified particles (Molecular Probes) were used as
provided. Size and zeta potential (surface charge) were determined by dynamic light
scattering and laser Doppler anemometry, respectively, using a ZS90 Zetasizer (Malvern
Instruments, MA, USA). Size measurements were performed at 25°C at a scattering angle of
90°.
Pretreatment of CF sputum with mucolytic agents
A 1 M solution of NAC (Sigma-Aldrich, MO, USA) was prepared and the pH was adjusted
to approximately 7.0 with NaOH, since its mucolytic activity is optimal with a pH of 7.0–9.0
[18]. NAC was added to CF sputum to a final concentration of 20 mM (2% dilution of CF
sputum), gently mixed by swirling with a pipette tip and incubated for 30 min at 37°C, prior
to the addition of nanoparticles.
Multiple particle tracking in CF sputum
Nanoparticles were added to approximately 350 μl of CF sputum (3% dilution; final
concentration 0.008% wt/vol) with or without NAC pretreatment, transferred to eight-well
glass chambers (LabTek, CA, USA), and equilibrated for 2 h at 37°C prior to microscopy.
The dynamics of particles were quantified using multiple particle tracking [13,14,23,24].
Briefly, 20 s movies at 67 ms temporal resolution were acquired via a silicon-intensified
target camera (VE-1000, Dage-MTI, IN, USA) on an inverted epifluorescence microscope
(Axiovert, Zeiss, NY, USA) with a 100X/1.4 NA objective. Movies were analyzed with
Metamorph software (Universal Imaging, WI, USA) to extract x, y positional data over time.
Time-averaged mean square displacement (MSD) and Deff for each particle were calculated
as a function of time scale (τ) [23–25]. CF sputum was assumed to be locally isotropic but
not necessarily homogeneous; 2D diffusivity is equal to 3D diffusivity under this condition
[23]. Bulk transport properties were calculated by geometric ensemble-averaging of
individual transport rates. The tracking resolution was 10 nm, determined by tracking the
displacement of particles immobilized with a strong adhesive [26]. Particle transport
mechanism (immobile, hindered and diffusive) was classified as discussed previously
[24,27].
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Determination of the mesh spacing of CF sputum
The mesh spacing of CF sputum was estimated based on fitting an obstruction-scaling model
to measured particle diffusion rates, using maximum likelihood estimation [28]. This model
was previously adapted to characterize mucus mesh spacing based on virus and DNA
diffusion [29,30]. The model is valid in cases where there is negligible interaction between
particles and mesh, and where fluids between the mesh elements exhibit the viscous drag
(microviscosity) of water. Unlike human mucus from healthy volunteers, fluids between the
CF sputum mesh have markedly higher concentrations of free bio-polymers, including DNA
and actin fragments [5], rendering the microviscosity significantly higher. Thus, we adapted
this model by replacing the viscosity of water with the viscosity of fluids in the pores of CF
sputum, which was previously estimated, based on the diffusion of dextran in CF sputum, to
be approximately 2.9-fold higher than that of water [5].
Scanning electron microscopy
Scanning electron microscopy (SEM) was performed to offer visual confirmation of possible
changes in sputum structure upon NAC treatment. Either native or NAC-treated CF sputum
was fixed in 2% glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.2) containing 3
mM CaCl2 for 1 h, subsequently rinsed in buffer and postfixed in 1% OsO4 in 0.1 M sodium
cacodylate buffer for 1 h on ice in the dark. Following a brief rinse with distilled water,
samples were stained with 2% uranyl acetate for 1 h and then dehydrated through a graded
series of ethanol solutions. Upon complete dehydration, samples were soaked in a 50:50
mixture of ethanol and hexamethyldisilazane (HMDS), followed by pure HMDS. Sputum
samples were then dessicated under vacuum, sputter-coated with 20 nm of Au/Pd and
observed with a field-emission scanning electron microscope (LEO 1530 FE-SEM, Zeiss)
operating at 1–3 kV. SEM most likely introduces artifacts that make it unsuitable for
quantitative estimates of pore sizes in the sputum microstructure [13].
Statistical analysis
Statistically significant differences between two groups were analyzed with a one-tailed
Student's t-test, assuming unequal variances.
Results
Transport of PEG-coated & uncoated 200 nm particles in native & NAC-treated CF sputum
Using PS beads as model gene/drug carriers, we first measured the penetration rates of 200
nm uncoated and PEG-coated PS particles (PS and PS-PEG, respectively) in native CF
sputum (SUPPLEMENTARY MOVIES 1 & 2, see online
www.futuremedicine.com/doi/suppl/10.2217/nnm.10.123). The reduced mucoadhesion of
200 nm PS-PEG particles compared with uncoated 200 nm PS particles was confirmed by
the greatly improved geometric averaged ensemble MSD (<MSD>) over all time scales in
native sputum, as well as the values that were in good agreement with our previous findings
(FIGURE 1A & TABLE 1) [13].
We hypothesized that the transport of 200 nm PS-PEG particles could be further improved
by reducing steric hindrance imposed by the dense mesh of CF sputum. Therefore, we
altered the structural/barrier properties of CF sputum by pretreating it with NAC. We found
that NAC treatment further increased the particle penetration rates, as measured by <MSD>,
of 200 nm PEG-coated particles by approximately tenfold over the same particles in native
sputum (at τ = 1 s; FIGURE 1A & SUPPLEMENTARY MOVIE 3) (p < 0.05). Importantly, the average transport
rate of 200 nm PS-PEG particles in NAC-treated sputum corresponds to a speed only
approximately eightfold slower than their theoretical speeds in water (τ = 1 s) (TABLE 1). We
also evaluated the extent of impediment to particle transport in CF sputum by the equation
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<MSD> = 4Doτα, where Do is the τ-independent particle diffusivity and α is the anomalous
diffusion exponent that signifies the extent of impediment to particle penetration (α = 1 for
pure unhindered Brownian diffusion; α approaches zero as obstruction to particle diffusion
increases). The average α value was 0.91 for 200 nm PS-PEG in NAC-treated CF sputum,
compared with 0.70 for the same particles in native sputum, suggesting that the transport of
200 nm PS-PEG is minimally hindered in NAC-treated sputum.
Since fast moving outlier nanoparticles represent a subpopulation that is more likely to
readily penetrate the sputum barrier, we characterized the heterogeneity in the transport of
individual particles by plotting the distribution of the logarithms of individual particle
effective diffusivities (Deff) at τ = 1 s (FIGURE 1B). Over 85% of 200 nm PS-PEG particles
exhibited Deff greater than 0.1 μm2/s in NAC-treated sputum, a marked increase over the
approximately 35% estimate for the same particles in native sputum. We also classified the
mechanisms of particle transport into three non-overlapping transport modes (immobile,
hindered and diffusive; where rates of movement, diffusive > hindered > immobile) (FIGURE 1C).
Based on this analysis, approximately 65 and 35% of 200 nm PS-PEG particles were
classified as undergoing unhindered diffusion in NAC-treated and native CF sputum,
respectively. The average transport rate of the diffusive fraction of 200 nm PS-PEG particles
in NAC-treated sputum is only approximately fourfold slower than that for the same
particles in water, which is similar to the average speed previously reported for 200 nm PS-
PEG particles in fresh, unaltered CVM obtained from donors with healthy vaginal flora
(without CF) [14]. We next estimated the fraction of particles that may penetrate a 10 μm-
thick CF sputum layer as a function of time, based on fitting the τ-dependent Deff for
individual particles over long time scales to Fick's second law of diffusion (FIGURE 2) [13].
Based on this analysis, over 75% of 200 nm PS-PEG particles are capable of penetrating
across a 10-μm-thick NAC-treated sputum layer in 20 min, compared with approximately
35% for the same particles in native sputum (p < 0.01) (FIGURE 2).
The substantial improvement in the transport rates of 200 nm particles mediated by NAC
treatment was evident only with the particles that were densely coated with PEG; the
transport of uncoated 200 nm PS particles was strongly retarded by sputum pretreated with
NAC (SUPPLEMENTARY MOVIE 4). The <Deff> for uncoated 200 nm PS particles in NAC-treated
sputum (τ = 1 s) remained approximately 530-fold slower than the same particles in water
(TABLE 1). There is little difference in the distribution of individual Deff for uncoated 200 nm
particles in native and NAC-treated sputum (FIGURE 1B), and over 90% of 200 nm PS particles
in NAC-treated CF sputum were classified as immobilized or strongly hindered (FIGURE 1C).
Transport of PEG-coated & uncoated 500 nm particles in native & NAC-treated CF sputum
We next investigated if adjuvant NAC treatment can also enhance the transport rates of 500
nm PS-PEG particles in CF sputum. We first measured the transport rates of 500 nm PS and
PS-PEG particles in native sputum. In good agreement with our previous findings, a dense
PEG coating only mediated minor improvements in the transport of 500 nm particles, as
reflected by the approximately fivefold greater <MSD> at a time scale (τ) of 1 s (FIGURE 3A).
The average transport rate of the 500 nm PS-PEG particles remained approximately 350-
fold slower than their theoretical rates in water (TABLE 1), indicating that the PEG coating alone
on 500 nm particles was unable to overcome the strong retardation by the sputum mesh.
To enhance the sputum penetration of 500 nm PS-PEG particles, CF sputum was again
pretreated with NAC. The average <MSD> of 500 nm PS-PEG particles increased threefold
upon NAC treatment (τ = 1 s) (FIGURE 3A); this improvement was observed in all sputum
samples tested (p < 0.001). The α values were 0.46 and 0.73 for PS-PEG particles in native
and NAC-treated sputum, respectively (TABLE 1), confirming that NAC significantly reduced
the diffusional barrier property of CF sputum. Overall, the transport of 500 nm PS-PEG
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particles in CF sputum pretreated with NAC was slowed by only an average of
approximately 100-fold compared with their theoretical speeds in water.
We observed a substantial fraction of fast moving 500 nm PS-PEG particles in CF sputum
pretreated with NAC; over 20% of 500 nm PS-PEG particles exhibited Deff (τ = 1 s) larger
than 0.1 μm2/s in NAC-treated sputum (FIGURE 3B). By contrast, we found no particle displayed
Deff (τ = 1 s) larger than 0.1 μm2/s in native sputum. Based on transport mode analysis,
while over 98% of 500 nm PS-PEG particles in native sputum were immobilized or strongly
hindered, more than 40% of 500 nm PS-PEG particles underwent nearly unhindered
diffusion in NAC-treated sputum (FIGURE 3C), with <Deff> only approximately sixfold lower
than that for the same particles in water (data not shown). The large percentage of 500 nm
PS-PEG undergoing unhindered transport is in good agreement with a substantial fraction of
fast moving particles, as shown in the individual Deff distribution analysis (FIGURE 3B).
Polyethylene glycol coatings were critical for the improved transport of 500 nm particles
mediated by NAC, since uncoated 500 nm PS particles remained strongly hindered by CF
sputum pretreated with NAC. The difference in <MSD> was not statistically significant for
500 nm PS particles in native and NAC-treated sputum (τ = 1 s), owing to the large overlap
in the distribution of individual particle Deff (FIGURE 3A & 3B). Over 95% of uncoated particles
were immobilized or trapped in both native and NAC-treated sputum (FIGURE 3C). Overall, the
<Deff> of uncoated 500 nm PS particles was approximately 1600- and 1000-fold lower in
native and NAC-treated sputum, respectively, compared with the same particles in water
(TABLE 1).
Based on our measurements in combination with Fick's second law of diffusion,
approximately 30% of 500 nm PS-PEG particles were classified as capable of penetrating a
10-μm-thick NAC-treated sputum layer in 20 min, and approximately 40% within 2 h (FIGURE
4). Less than 5% of 500 nm PS-PEG particles in native sputum, as well as less than 1% and
approximately 4% for 500 nm uncoated particles in native and NAC-treated sputum,
respectively, were expected to do so within 20 min. The differences in the estimated
penetrable fractions between 500 nm PS-PEG in NAC-treated sputum and all other
conditions were statistically significant (p < 0.05).
3D interfiber spacing of native & NAC-treated CF sputum
By fitting the measured speeds of 200 and 500 nm PS-PEG particles, along with published
data on transport rate of FITC-dextran, to an obstruction-scaling model, we previously
estimated the average distance between mucin fibers (i.e., mesh spacing) of fresh, undiluted
and unaltered CF sputum to be approximately 140 ± 50 nm [13]. Using the same technique,
we found that NAC treatment increased the average mesh spacing of CF sputum samples
tested here from 145 ± 50 nm to 230 ± 50 nm (p < 0.001). The pore sizes were also
substantially more heterogeneous in NAC-treated sputum (50–1300 nm) compared with
native sputum (50–300 nm), with a large fraction of pores in NAC-treated sputum in excess
of 300 nm (FIGURE 5A & 5B). The increased fraction of larger pores upon NAC treatment was also
visually confirmed with scanning electron m icrographs (FIGURE 5C & 5D).
Discussion
Cystic fibrosis sputum represents a tenacious diffusional barrier to aerosol drug and gene
carriers due to its elevated viscoelasticity [11,16,17]. Previous attempts to overcome the
sputum barrier largely focused on using mucolytics to reduce the barrier property of CF
sputum, but showed little success [6,7,31–33]. More recently, we have engineered particles
with muco-inert coatings, and shown that these nanoparticles can exhibit diffusion in CF
sputum at appreciable rates for the first time [11,13]. Nevertheless, neither approach alone
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facilitated particle penetration at rates we have previously observed in human CVM
obtained from healthy volunteers [14,15], and large fractions of particles remained
effectively trapped or greatly slowed in CF sputum. Hindered particle transport is most
likely attributed to a mucus mesh that is expected to be substantially denser for CF sputum
than CVM. We previously estimated the average mesh spacing of minimally perturbed CF
sputum (~140 ± 50 nm) [13] to be substantially smaller than that for CVM (~340 ± 70 nm)
[28]. This difference is likely a consequence of the elevated solid content in CF sputum
compared with normal mucus [34].
In the present study, large fractions of nanoparticles are shown to penetrate NAC-treated CF
sputum at speeds approaching those in water, most likely enabling much greater fractions of
particles to penetrate the thick sputum layer. Improved penetration of nanoparticles through
CF sputum holds important implications for CF therapeutics, including gene therapy. In
previous CF gene therapy clinical trials using synthetic nonviral systems, such as liposome-
and polymer-based gene carriers, partial correction of the chloride ion imbalance in the
nares of CF patients has been observed [35,36]. However, the sputum barrier is not as
pronounced in the nares as in the CF airways. In one trial that showed partial restitution of
chloride abnormality in the lower CF airways, there was no evidence of normalization in
sodium ion imbalance, which caused CF sputum to remain dehydrated and, hence, muco
ciliary clearance impaired [3]. The lack of sodium abnormality restitution likely reflects
inadequate gene transfer, since, while complete correction of the chloride ion abnormality
can be achieved with as little as 5% cells expressing functional CFTR, a much larger
fraction of cells (~25%) must express functional CFTR before sodium abnormality is fully
reversed in vitro [37,38]. While poor gene transfer has been attributed by some to limited
cellular uptake across the apical membrane, unproductive intracellular trafficking,
suboptimal promoters, toxicity and immunological barriers [35,39,40], limited transport of
gene carriers across the sputum barrier is increasingly recognized as a critical bottleneck to
gene transfer to airway cells [11,16]. Enhanced sputum penetration by gene carriers, based
on a combined particle surface chemistry and mucolytics strategy, will most likely increase
the number of gene carriers that reach target epithelia and, hence, improve CF gene therapy.
The improved particle transport rates observed here are most likely attributed to increased
sputum pore sizes, including a substantial fraction of pores (~12%) in excess of 500 nm.
Larger pores will reduce the steric obstruction that limits particle penetration across CF
sputum. Nevertheless, NAC treatment of sputum only enhanced the penetration rates of
particles that do not adhere to sputum, indicating that coating particles with a muco-inert
surface is essential for rapid particle penetration across sputum, even when the sputum mesh
spacing is greatly increased. Our observations suggest that previous failures to observe
marked improvements in particle transport upon treatment with mucolytics may be
attributed to extensive particle adhesion to the residual sputum mesh. For example, Shute
and coworkers demonstrated that NAC did not improve the transport of PS particles in
synthetic CF sputum fluids (i.e., physical mixture of porcine mucins, DNA and actin
filaments) [41]; PS particles are strongly mucoadhesive [13,14]. It is also worth noting that
previous studies investigating the effects of another common mucolytic, rhDNase, on
particle transport in CF sputum were performed with mucoadhesive PS particles, which may
explain the negligible benefits observed [6,7].
It was not obvious, a priori, that NAC would improve the diffusion of nanoparticles in CF
sputum since it is controversial whether mucin is even the primary constituent of the sputum
mesh. Previous work has suggested CF sputum to be a mesh network composed primarily of
DNA and actin, with almost no intact mucins or little mucin content [42]. By contrast, others
have reported that mucin is the most abundant macromolecule in CF sputum, and that the
higher mucin content in CF causes an increase in the bulk rheological properties of CF
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sputum [7,16]. Another study demonstrated that the weight-averaged molecular weight of
mucins in CF sputum was found to be similar to that in normal mucus [43,44], which
suggests the mucins in CF sputum may not be substantially fragmented. Whether mucin
comprises the sputum mesh is perhaps dependent on the patient and the disease stage [45].
In the CF sputum samples we used, we found the mucin content to be substantially greater
than the DNA content (data not shown), suggesting that mucins were the primary structural
component of the sputum mesh in this study.
It remains unclear exactly how NAC increases the pore sizes in sputum. Dawson and
coworkers previously showed that rhDNase offered little to no improvement in nanoparticle
transport in CF sputum [6]. In fact, elimination of fast and slow moving outlier particles
upon treatment of sputum with rhDNase led the authors to suggest that rhDNase may induce
a higher microviscosity (viscosity in the watery channels) in CF sputum due to the release of
soluble DNA fragments. By contrast, NAC did not increase the microviscosity of CF
sputum, since the diffusive fraction of 200 nm PS-PEG particles in NAC-treated sputum
exhibited speeds only approximately fourfold slower than the same particles in pure water,
which is comparable to a previous observation that FITC-dextran is slowed approximately
threefold in native CF sputum compared with in water [5]. That NAC did not increase the
sputum microviscosity was unexpected a priori, since NAC cleaves disulfide crosslinks and,
therefore, was expected to release mucins into the low viscosity interstitial fluids between
sputum mesh; soluble mucin molecules that diffused into the pores of the sputum mesh
would be expected to increase the microviscosity of CF sputum far more than the relatively
small DNA fragments liberated by rhDNase (longer polymers increase viscosity to a much
greater extent than shorter polymers at the same concentration [46]). One possible
explanation that can reconcile our various findings is that NAC may not induce release of
soluble mucin. Instead, cleaved mucin fibers may remain associated with the sputum mesh
via entanglements, hydro phobic interactions or other adhesive interactions [47], which led
to larger pores without releasing soluble mucins that can increase the viscosity of interstitial
fluid.
In the present study, a final NAC concentration of 20 mM in sputum was chosen based on
previous work by King and coworkers that estimated the maximum concentration of NAC to
be approximately 20 mM in dog airways (assuming a 10% deposition in the trachea and
major bronchi via a metered dose inhaler) [48]. This NAC dose decreased mucus
viscoelasticity and improved clearance without any evident side effects. A higher dose of
mucolytics may be delivered to the airways; the deposition of nacystelyn, a lysine derivative
of NAC, was approximately three-times greater when administered to healthy volunteers via
a dry powder inhaler [49]. The NAC dose used in this study did not destroy the CF sputum
network structure, as shown by scanning electron micrographs and as suggested by the fact
that uncoated particles were effectively immobilized by adhesion to the visco elastic residual
sputum mesh. A tenfold lower NAC dose (2 mM) also enhanced particle penetration across
CF sputum to a similar extent; however, further reduction in NAC dose (0.2 mM)
substantially reduced the adjuvant effects of NAC (data not shown).
Rapid sputum penetration of substantial fractions of 500 nm particles may have important
implications for numerous CF therapeutic applications, since larger particles offer improved
encapsulation of a wider array of drugs, as well as controlled drug-release kinetics over
longer times [50,51]. It is worth noting that PEG coating on nanoparticles most likely resists
adsorption of NAC, and thus the presence of NAC should not affect the degradation kinetics
of the biodegradable nanoparticles or the rate of drug release. Use of other mucolytic agents,
which act on other major sputum constituents, such as DNA and filamentous actins, in
combination with NAC, may further enhance the penetration of large nanoparticles in CF
sputum. Hypertonic saline, known to augment airway surface liquid volume and decrease
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airway surface liquid viscosity [52], should also be considered as an adjuvant to improve the
sputum penetration of nanoparticles in CF patients.
Conclusion
N-acetyl cysteine treatment of CF sputum greatly increased the mesh spacing, thereby
allowing large fractions of polymeric nanoparticles to rapidly penetrate NAC-treated CF
sputum if the nanoparticles possess non-mucoadhesive surfaces. Non-mucoadhesive
nanoparticles were achieved here through coatings with a dense brush layer of low-
molecular-weight PEG. This combined mucolytics/nanoparticle-coating strategy has
significant therapeutic implications for CF and possibly other pulmonary diseases
characterized by excess mucus production, since the sputum barrier has been increasingly
recognized as a major hurdle to airway gene and drug delivery.
Future perspective
A combined mucolytics/nanoparticle-coating strategy that enables particles as large as 500
nm to penetrate sputum layers is introduced here. We expect our approach will facilitate
improved retention and distribution of drug carriers in the CF lung, enabling sustained
delivery of a wide range of therapeutics. This approach may also facilitate more efficient
gene therapy of the CF lungs.
Executive summary
■ Existing approaches to improve particle diffusion across cystic fibrosis (CF)
sputum, either by using mucolytic adjuvants or reducing particle adhesion to
the sputum mesh, do not facilitate rapid diffusion of particles at rates
comparable to those previously observed for nanoparticles in human
cervicovaginal mucus.
■ Simultaneously reducing the CF sputum barrier with N-acetyl cysteine
(NAC) and reducing particle–mucin adhesion with muco-inert coatings
synergistically enhances particle penetration across CF sputum.
■ Polyethylene glycol-coated 200 nm particles can rapidly penetrate NAC-
treated sputum with average speeds approaching their theoretical speeds in
water.
■ Combining polyethylene glycol coatings and adjuvant NAC strategy allows
sputum penetration by larger particles (i.e., 500 nm) that are otherwise
trapped in CF sputum.
■ NAC most likely enhances the diffusion of nanoparticles in sputum by
increasing the mesh spacings of the dense CF sputum mesh.
■ Rapid diffusion is critically dependent on the presence of a muco-inert
coating on nanoparticles; NAC alone only marginally improved the sputum
penetration of conventional nanoparticles.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Transport of 200 nm uncoated (PS) and polyethylene glycol-coated (PS-PEG)
polystyrene nanoparticles in native or N-acetyl cysteine-treated cystic fibrosis sputum
(A) <MSD> as a function of time scale (τ). (B) Distribution of the logarithms of individual
particle Deff at a time scale of 1 s. (C) Percentage of particles that undergo unhindered
diffusive transport in native or NAC-treated cystic fibrosis sputum. Data represents three
individual experiments, with n > 200 particles for each experiment.
*Statistically significant differences (p < 0.05).
Deff: Effective diffusivity; MSD: Mean square displacement; NAC: N-acetyl cysteine; PEG:
Polyethylene glycol; PS: Polystyrene.
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Figure 2. Fraction of 200 nm uncoated (PS) and polyethylene glycol-coated (PS-PEG) particles
that are expected to penetrate a 10 μm cystic fibrosis sputum layer over time
Ratio of particle concentration at ΔL = 10 μm deep (CΔL) to initial particle concentration at
the surface (Co) over time. Data represents three individual experiments, with n > 200
particles for each experiment. Error bars indicate standard error of the mean.
*Statistically significant differences compared with three other conditions (p < 0.01).
C: Concentration; NAC: N-acetyl cysteine; PEG: Polyethylene glycol; PS: Polystyrene.
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Figure 3. Transport of 500 nm uncoated (PS) and polyethylene-coated (PS-PEG) polystyrene
nanoparticles in native or N-acetyl cysteine-treated cystic fibrosis sputum
(A) <MSD> as a function of time scale (τ). (B) Distribution of the logarithms of individual
particle Deff at a time scale of 1 s. (C) Percentage of particles that undergo unhindered
diffusive transport in native or NAC-treated CF sputum. Data represents three individual
experiments, with n > 200 particles for each experiment.
*Statistically significant differences (p < 0.05).
Deff: Effective diffusivity; MSD: Mean square displacement; NAC: N-acetyl cysteine; PEG:
Polyethylene glycol; PS: Polystyrene.
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Figure 4. Fraction of 500 nm uncoated (PS) and polyethylene glycol-coated (PS-PEG) particles
that are expected to penetrate 10 μm cystic fibrosis sputum layer over time
Ratio of particle concentration at ΔL = 10 μm deep (CΔL) to initial particle concentration at
the surface (Co) over time. Data represents three individual experiments, with n > 200
particles for each experiment. Error bars indicate standard error of the mean.
*Statistically significant differences compared with three other conditions (p < 0.01).
C: Concentration; NAC: N-acetyl cysteine; PEG: Polyethylene glycol; PS: Polystyrene.
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Figure 5. 3D microstructures of cystic fibrosis sputum
(A & B) Pore size distribution of (A) native and (B) NAC-treated cystic fibrosis sputum.
The average pore sizes predicted for 200 and 500 nm polystyrene–polyethylene glycol
nanoparticles by the obstruction-scaling model are 145 ± 50 nm and 230 ± 50 nm for native
and NAC-treated CF sputum, respectively. (C & D) Scanning electron micrographs of (C)
native and (D) NAC-treated CF sputum. There is an increase in the fraction of larger pores
upon NAC treatment.
NAC: N-acetyl cysteine.
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